Olema Pharmaceuticals (OLMA) Equity Average (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Equity Average data on file, last reported at $479.5 million in Q1 2026.

• Equity Average for Q1 2026 came in at $479.5 million, up 21.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $479.5 million (up 21.03% YoY), and the FY2025 annual result was $443.8 million, up 33.89% from the prior year.
• Equity Average advanced to $479.5 million in Q1 2026 per OLMA's latest filing, from $393.0 million in the prior quarter.
• Over five years, Equity Average peaked at $479.5 million in Q1 2026 and troughed at $168.3 million in Q2 2023.
• A 5-year average of $279.5 million and a median of $250.7 million in 2022 frame the typical range for Equity Average.
• The sharpest annual moves came in 2023 and 2025: Equity Average plunged 32.87% in 2023, then jumped 61.65% in 2025.
• A 5-year view of Equity Average shows it stood at $207.6 million in 2022, then gained by 27.4% to $264.5 million in 2023, then gained by 14.9% to $303.9 million in 2024, then increased by 29.31% to $393.0 million in 2025, then grew by 22.01% to $479.5 million in 2026.
• Business Quant data shows OLMA's Equity Average at $479.5 million in Q1 2026, $393.0 million in Q4 2025, and $326.4 million in Q3 2025.